Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peptide YY3-36 - Gila Therapeutics

Next Previous
Drug Profile

Peptide YY3-36 - Gila Therapeutics

Alternative Names: GT 001 - Gila Therapeutics; GT 002 - Gila Therapeutics; GT 003 - Gila Therapeutics; GT-001; GT-002; GT-003; Peptide YY (3-36); Peptide YY3-36; PYY(3-36); PYY3-36

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gila Therapeutics
  • Class Antihyperglycaemics; Hormones; Obesity therapies; Peptides
  • Mechanism of Action Peptide YY (3-36) replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Diabetes mellitus; Obesity

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Obesity(In volunteers) in USA (PO)
  • 31 Jan 2023 GT 001 is still in phase I trials for Obesity in USA (Gila Therapeutics pipeline, January 2023)
  • 31 Jan 2023 Gila Therapeutics plans to initiate second clinical study in Obesity (Gila Therapeutics pipeline, January 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top